Literature DB >> 16475043

The standard is still the standard or why an INR of 2-3 is still the optimal intensity for secondary prevention of venous thromboembolism.

Michael J Kovacs1.   

Abstract

The optimal intensity of warfarin anticoagulation for secondary prevention of venous thromboembolism is debatable. Recent studies have shed light on the issue. The two pivotal studies, ELATE and PREVENT, are reviewed and discussed. Although the ELATE and PREVENT studies offer different conclusions, the results of the two studies are consistent with each other. Low intensity warfarin is more efficacious than placebo, although it is less efficacious than standard intensity and offers no safety advantage. For long term secondary prophylaxis of spontaneous venous thromboembolism, the optimal INR intensity of warfarin remains 2.0-3.0.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16475043     DOI: 10.1007/s11239-006-5577-6

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  10 in total

1.  Risk of recurrent venous thomboembolism--expanding the frontier.

Authors:  Martin H Prins; Antonio Marchiori
Journal:  Thromb Haemost       Date:  2002-01       Impact factor: 5.249

2.  The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

Authors:  S Schulman; S Granqvist; M Holmström; A Carlsson; P Lindmarker; P Nicol; S G Eklund; S Nordlander; G Lärfars; B Leijd; O Linder; E Loogna
Journal:  N Engl J Med       Date:  1997-02-06       Impact factor: 91.245

3.  Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.

Authors:  G Agnelli; P Prandoni; M G Santamaria; P Bagatella; A Iorio; M Bazzan; M Moia; G Guazzaloca; A Bertoldi; C Tomasi; G Scannapieco; W Ageno
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

4.  A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.

Authors:  C Kearon; M Gent; J Hirsh; J Weitz; M J Kovacs; D R Anderson; A G Turpie; D Green; J S Ginsberg; P Wells; B MacKinnon; J A Julian
Journal:  N Engl J Med       Date:  1999-03-25       Impact factor: 91.245

5.  Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.

Authors:  Paul M Ridker; Samuel Z Goldhaber; Ellie Danielson; Yves Rosenberg; Charles S Eby; Steven R Deitcher; Mary Cushman; Stephan Moll; Craig M Kessler; C Gregory Elliott; Rolf Paulson; Turnly Wong; Kenneth A Bauer; Bruce A Schwartz; Joseph P Miletich; Henri Bounameaux; Robert J Glynn
Journal:  N Engl J Med       Date:  2003-02-24       Impact factor: 91.245

Review 6.  Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Harry R Büller; Giancarlo Agnelli; Russel D Hull; Thomas M Hyers; Martin H Prins; Gary E Raskob
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

7.  Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.

Authors:  Clive Kearon; Jeffrey S Ginsberg; Michael J Kovacs; David R Anderson; Philip Wells; Jim A Julian; Betsy MacKinnon; Jeffrey I Weitz; Mark A Crowther; Sean Dolan; Alexander G Turpie; William Geerts; Susan Solymoss; Paul van Nguyen; Christine Demers; Susan R Kahn; Jeannine Kassis; Marc Rodger; Julie Hambleton; Michael Gent
Journal:  N Engl J Med       Date:  2003-08-14       Impact factor: 91.245

8.  Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor.

Authors:  C Kearon; J S Ginsberg; D R Anderson; M J Kovacs; P Wells; J A Julian; B Mackinnon; C Demers; J Douketis; A G Turpie; P Van Nguyen; D Green; J Kassis; S R Kahn; S Solymoss; L Desjardins; W Geerts; M Johnston; J I Weitz; J Hirsh; M Gent
Journal:  J Thromb Haemost       Date:  2004-05       Impact factor: 5.824

9.  Low-dose warfarin in atrial fibrillation leads to more thromboembolic events without reducing major bleeding when compared to adjusted-dose--a meta-analysis.

Authors:  Christine Perret-Guillaume; Denis G Wahl
Journal:  Thromb Haemost       Date:  2004-02       Impact factor: 5.249

10.  Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation.

Authors:  Margaret C Fang; Yuchiao Chang; Elaine M Hylek; Jonathan Rosand; Steven M Greenberg; Alan S Go; Daniel E Singer
Journal:  Ann Intern Med       Date:  2004-11-16       Impact factor: 25.391

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.